All In Biotech

Drug Trial Radar · NCT05857163

Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection

Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

700

Actual

Start

May 18, 2023

Primary completion

Dec 24, 2023

Study completion Mar 26, 2024

Sponsor

Sponsor type
Industry
First posted
May 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in the primary treatment of participants with H. pylori infection using an adaptive design with sample size re-estimation.

Conditions

  • H.Pylori Infection

Interventions

  • Rifasutenizol capsulesDrug

    400 mg, BID, taken orally within half an hour after breakfast and dinner.

  • Rabeprazole sodium enteric-coated tabletsDrug

    20 mg, BID, taken orally within half an hour before breakfast and dinner.

  • Amoxicillin CapsulesDrug

    1 g, BID, taken orally within half an hour after breakfast and dinner.

  • Clarithromycin placebo tabletsDrug

    BID, taken orally within half an hour after breakfast and dinner.

  • Bismuth potassium citrate placebo capsulesDrug

    BID, taken orally within half an hour before breakfast and dinner.

  • Clarithromycin tabletsDrug

    500 mg, BID, taken orally within half an hour after breakfast and dinner.

  • Bismuth potassium citrate capsulesDrug

    240 mg, BID, taken orally within half an hour before breakfast and dinner.

  • Rifasutenizol placebo capsulesDrug

    BID, taken orally within half an hour before breakfast and dinner.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication Rate of H.Pylori InfectionTime frame: 4 to 6 weeks after the last dose of the study drugs

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.